Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting

... Isis and its collaborators presented results on antisense inhibition of novel targets that could offer new ... also presented new preclinical data showing that antisense inhibition of STAT5 resulted in potent anti-tumor ... sigma RNA, a Marker for Carcinomas" showed that antisense inhibition of Malat-1 altered the splicing of ...

Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day

... Inc. (Nasdaq: ISIS ), the leader in antisense therapeutics, today announced that management ... has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug ... diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of ...

Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug

... ISIS-SGLT2Rx - Isis' first kidney-targeted antisense drug for type 2 diabetes enters clinical ... has initiated a Phase 1 study of ISIS-SGLT2Rx, an antisense drug that inhibits the production of sodium ... "ISIS-SGLT2Rx is among the most potent antisense drugs Isis has yet evaluated in preclinical ...

Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer

... Phase 2 study of AEG35156, their targeted antisense therapeutic in mid-stage development for multiple ... of the X-Linked Inhibitor of Apoptosis (XIAP) antisense AEG35156 Given In Combination With ... apoptotic triggers. AEG35156, a second generation antisense which targets XIAP, is designed to lower the ...

Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting

... from its phase 1/2 clinical trial of the XIAP antisense oligonucleotide, AEG35156, will be highlighted in ... is entitled "Phase I/II Trial of the XIAP antisense Oligonucleotide (AEG35156) in Combination with ... Study of Phase 1/2 Trial of the XIAP antisense Oligonucleotide (AEG35156) in Combination with ...

Isis Reports Financial Results and Highlights for Third Quarter of 2008

... because of the speed and productivity of our antisense drug discovery platform, which enables us ... million in sublicensing revenue from Alnylam and antisense Therapeutics Limited (ATL). Operating Expenses ... and initiated clinical studies on two exciting antisense drugs. We continue to make progress in every ...

Isis Reports Financial Results and Highlights for Second Quarter of 2008

... Pharmaceuticals, Inc. -- $1.4 million from antisense Therapeutics Limited -- $3.3 million from Ibis ... broad protection of mipomersen and other antisense apoB compounds. In addition to the successes of ... disease -- Granted broad patent coverage for antisense compounds targeting apolipoprotein B, U.S. ...

Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights

... will seek buyer for Ganite and terminates c-myb antisense program "Genta has successfully diversified ... programs appear below. Genasense: The Leading antisense Drug in Clinical Development Genasense in ... Company has also terminated its license to c-myb antisense due to diminishing patent life. The Company ...

BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE

... have an ongoing collaboration to identify antisense drugs that target proprotein ... able to identify and characterize a number of antisense drugs that inhibit PCSK9 in pre-clinical studies ... drug," said Brett Monia, Ph.D., Vice President of antisense Drug Discovery of Isis. "PCSK9 is a new ...

Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration

... cardiovascular patients that utilizes Isis' novel antisense technology. Isis will also be eligible to receive ... has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug ... metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety ...

Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions

... receive milestones and royalties on antisense drugs developed by Altair - Altair to conduct ... development and commercialization of Isis' antisense drugs to treat asthma and other respiratory ... is assembling a focused team of experts in both antisense drug discovery and development and respiratory ...

Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics

... of Single-Stranded antisense RNAi Drugs CARLSBAD, Calif., Oct. 3 ... the feasibility of using single-stranded antisense drugs to target the RNAi pathway. "We are ... chemistries and expertise to exploit antisense mechanisms, such as RNAi, for ....

Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases

... - Includes license of two antisense drugs in development targeting glucagon ... - Includes research collaboration to identify antisense drugs to inhibit additional targets ... company, to discover, develop and commercialize antisense drugs to treat metabolic diseases, including Type ...

Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia

... data for GTI-2040 in AML are consistent with an antisense mode of action, and the frequency of responses ... his team at OSU have extensive experience with antisense and other targeted therapies in ... to Ara-C. About GTI-2040 GTI-2040 is an antisense drug that specifically targets the R2 component ...

OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427

... Center Abstract: # 5012 Title: OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a ... development. OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS ), to ...

OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting

... Center Abstract: # 5012 Title: OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a ... . OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS ), to ...

Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis

... partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis is a ...

Isis' Ibis Biosciences Subsidiary Highlights the Power of the Ibis T5000 Pathogen Identification and Characterization System at the ICAAC/IDSA Meeting

... partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis ...

Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics

... partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis ...

OncoGenex increases economic interest in lead cancer drug OGX-011

... 3 trials. This has enabled us to continue to benefit from the successes of antisense drugs through a growing annuity of licensing fees, milestones and royalty ... clinical results to date have established OGX-011 as one of many promising antisense drugs and OncoGenex is now ideally situated to lead the final stages of ...

Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)

... (OSU) clinical team of a paper entitled "Phase I Study of GTI-2040, an antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in ... or relapsed AML. About LOR-2040 LOR-2040 (formerly GTI-2040) is an antisense drug that specifically targets the R2 component of ribonucleotide ...

Abbott Invests Additional $20M in Isis' Subsidiary Ibis Biosciences

... partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis ...

Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call

... partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis ...

Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity

... partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis ...

Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer

... partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis ...

OncoGenex Reports Second Quarter 2009 Financial Results

... phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS ), to effectively target and inhibit production of specific proteins in tumor cells. ...

OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering

... Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS ), to effectively target and inhibit production of specific proteins in tumor cells. ...

OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock

... Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS ), to effectively target and inhibit production of specific proteins in tumor cells. ...

OncoGenex Pharmaceuticals Added to Russell Indexes

... Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS ), to effectively target and inhibit production of specific proteins in tumor cells. ...

OncoGenex Pharmaceuticals Files Shelf Registration Statement

... Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS ), to effectively target and inhibit production of specific proteins in tumor cells. ...

OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer

... Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS ), to effectively target and inhibit production of specific proteins in tumor cells. ...

OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer

... Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS ), to effectively target and inhibit production of specific proteins in tumor cells. ...

OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial

... Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS ), to effectively target and inhibit production of specific proteins in tumor cells. ...

Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services

... to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry, fine chemical manufacture, custom peptides and antisense oligo production. Dalton provides cGMP manufacturing and sterile filling services to its customers at any stage of the regulatory process (Phase ...

OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer

... British Columbia based on discoveries made by researchers at the Prostate Centre at Vancouver General Hospital. OGX-011 utilizes second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS ), to effectively target and inhibit production of clusterin protein in tumor cells. ...

iCo Therapeutics Closes $1.3 Million Private Placement

... supporting completion of the ongoing study in patients with diffuse macular edema. iCo-007 is a product of our satellite company strategy to exploit antisense technology beyond our core areas of focus to provide new treatment options in a broad range of diseases. With the benefit of our strong financial ...

OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer

... British Columbia based on discoveries made by researchers at the Prostate Centre at Vancouver General Hospital. OGX-011 utilizes second generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS ), to effectively target and inhibit production of clusterin protein in tumor cells. ...

PolyOrg, Inc. Acquires a License to Manufacture and Distribute PNA Monomers Worldwide

... nucleases or proteases. These properties of PNA have made them extremely attractive for applications in molecular biology, diagnostics, as well as in antisense and anti-gene therapies. About PolyOrg, Inc: PolyOrg, Inc. provides a variety of synthesis related services that support academic, ...

Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences

... RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners ...

Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call

... RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners ...